Company: CRNX
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001193125-25-175498
Chunk: 3

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part II, Item 1A
Chunk 3
---
We do not believe that there have been any material changes to the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities 

None.

Item 4. Mine Safety Disclosures 

Not applicable.

Item 5. Other Information 

Rule 10b5-1 Trading PlansThe following members of our Board of Directors and/or officers adopted, modified, or terminated a trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c): 

       Name
        
       Title of Director or Officer
        
       Action
        
       Date of Action
        
       Duration of Plan
        
       Total Shares of Common Stock to be Sold

       Dana Pizzuti
        
       Chief Medical and Development Officer
        
       Termination of 10b5-1 plan
        
       May 20, 2025
        
       January 3, 2025 - December 31, 2025
        
       Up to 70,000 shares

       Dana Pizzuti
        
       Chief Medical and Development Officer
        
       Adoption of 10b5-1 plan
        
       May 21, 2025
        
       August 20, 2025 - September 2, 2026
        
       Up to 96,492 shares

       Isabel Kalofonos
        
       Chief Commercial Officer
        
       Adoption of 10b5-1 plan
        
       June 7, 2025
        
       January 1, 2026 - December 19, 2026
        
       Up to 12,500 shares